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Abstract
Ayurveda is one of the ancient systems of health care of Indian origin. Roughly translated into
"Knowledge of life", it is based on the use of natural herbs and herb products for therapeutic
measures to boost physical, mental, social and spiritual harmony and improve quality of life.
Although sheltered with long history and high trust, ayurveda principles have not entered
laboratories and only a handful of studies have identified pure components and molecular pathways
for its life-enhancing effects. In the post-genomic era, genome-wide functional screenings for targets
for diseases is the most recent and practical approach. We illustrate here the merger of ayurveda
and functional genomics in a systems biology scenario that reveals the pathway analysis of crude
and active components and inspire ayurveda practice for health benefits, disease prevention and
therapeutics.
No longer a crude view of the crude extracts
The word "Ayurveda" comprises of word a ¯yus meaning
"life" or "life principle", and the word veda, which refers
to a system of "knowledge". Thus "Ayurveda" roughly
translates as the "knowledge of life". Ayurveda is a 5000+
year-old system of Indian home medicine using natural
plant extracts. With over 400,000 registered Ayurveda
practitioners, this system of medicine remains as one of
the most ancient yet living tradition practiced widely in
India, Pakistan, Sri Lanka and in other countries. The
basic principle in Ayurveda is to give greater priority to
total wellness and health rather than to make selective
treatment. It has become very popular as it uses reagents
and remedies essentially drawn from nature and is both
eco- and bio-friendly. Ayurvedic medical system practices
the use of dry powder or crude extract, and assignment of
bioactivities to a particular compound is not preferred.
Interestingly, the mainstream pharmaceutical research is
also on its way towards veering from mono-molecular or
single target approach to combinations and multiple tar-
get strategies [1]. Perhaps, multi-site mechanisms of
action of herbal preparations from the crude extracts may
offer greater chances for success where conventional sin-
gle-site agents have been disappointing. Auspiciously,
many of these traditional herbal medicines are now
increasingly being appreciated with Western models of
integrative health sciences and evidence-based approach
both in research and practice. Several bioactive com-
pounds have emerged from research in Ayurvedic herbals.
Among others include, Rauwolfia alkaloids for hyperten-
sion, psoralens for vitiligo, Holarrhena alkaloids in amoe-
biasis, guggulsterones from Commiphora as hypolipidemic
agents, Mucuna pruriens for Parkinson's disease, bacosides
from Bacopa monnieri, antivirals from phyllanthins, with-
anolides and many other steroidal lactones and their gly-
cosides as immunomodulators [2-4].
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Despite the recent revolutions in biotechnology and
genome research, an estimated 80% of the world popula-
tion still has no access to modern medicine and obtain
benefits from the time-tested alternative systems of medi-
cine [5]. As more genomes have been sequenced and gene
functions elucidated, time has come to bring the valuable
ancient medicinal knowledge to the rapidly expanding
genomic landscapes. It is envisioned that systematic iden-
tification and characterization of gene targets could lead
to deeper appreciation of the chemo-diversity in an herb-
alist's "brown bag". It is, however, feared that by reducing
traditional medicine to their mere molecular effectors the
investigators could "lose sight of the forest for the trees".
And as such, inspired by the holistic character of tradi-
tional medicinal systems to study functions of drug-
responsive genes, we have entertained the idea of apply-
ing a systems biology perspective in comparing gene reg-
ulatory circuits in an herbal preparation vis-à-vis some of
its bioactive components. A global accounting of molecu-
lar pathways depicted by a cellular wiring diagram would
offer an appreciation of how the activity of individual
component–by influencing each other–ultimately trans-
lates into the phenotypic response of a target cell, e.g.
tumor. The manuscript presents the concept of systems
biology for herbal medicine and the implications of our
recent cell-based functional genomic work towards clari-
fying the anti-cancer properties of one of the most prom-
inent therapeutic plant of Ayurveda, the Ashwagandha
(ASH).
From the active component to crude extract of 
Ashwagandha (ASH) – back to basics?
ASH (Withania somnifera), also known as winter cherry,
Indian ginseng or rasayana, is a member of GRAS (Gener-
ally Regarded As Safe) plants and a popular home remedy
in the Indian pharmacopoeia. Among the Ayurvedic
plants, pharmacological and biochemical studies in ASH
have been among the most extensive. Its crude extract is
included in commercial formulations prescribed for some
musculoskeletal problems (e.g., arthritis and rheuma-
tism), and as a general tonic for overall health and longev-
ity [6]. Despite being under-appreciated in the area of
oncology [7], experiments in test tubes and in animal
models demonstrated that ASH plays an anticancer role
by inducing apoptosis and cell cycle arrest, enhancing the
immune system, and inhibition of angiogenesis and
metastasis. Interestingly, as ASH exhibits both anti-oxi-
dant and pro-oxidant activities, it has been reported to
sensitize tumors to radiation while presenting itself a
radio/chemo-protector for normal cells. As this section
covers a review of the anti-cancer properties of ASH and its
bioactive components, readers will find the recent com-
pendia on its various therapeutic benefits very useful [6-
9].
P. Uma Devi, a radiation biologist from Jawaharlal Nehru
Cancer Hospital and Research Centre (Manipal, India),
was one of the early pioneers to research on ASH effects
on cancer growth. When crude alcoholic extract from ASH
roots was i. p.-injected (200–1000 mg/kg body wt daily
for 15 days) in mice, complete regression of injected sar-
coma occurred within 100 days [10]. They extended the
usefulness of ASH as an anti-cancer agent from a radiation
oncology perspective by demonstrating its synergism with
other treatment modalities, namely radiotherapy (10 Gy
gamma-irradiation) and hyperthermia (43°C for 30
min), a phenomenon that was related to depletion of cel-
lular glutathione with ASH treatment [11]. They demon-
strated that the cumulative doses of the extract (500–750
mg/kg daily) did not show any toxicity, in contrast to pure
withaferin A that was toxic even at a low dose. The results
supported the importance of ASH extract as a novel candi-
date herbal clinical sensitizer. But before such apprecia-
tion of clinical uses of crude extracts came to fore, it is
noteworthy that it had taken almost two decades since the
first series of reports on the anti-neoplastic potentials of
the purified component withaferin A were published [12-
15].
ASH has been proposed to regulate the cell cycle and
apoptosis pathways in several ways depending on the cell
type. First, a methanolic leaf extract of ASH (LASH) was
demonstrated to restore normal p53 function in tumor
cells bearing mutated copies. Further purification of the
tumor-selective inhibitory factor (dubbed as i-Factor)
ascribed novel anti-cancer functions to withanone
[16,17]. Second, in cases when tumors were p53-null, i.e.,
HL-60 leukemia cells, the LASH caused apoptosis by
down-regulation of bcl-2, cytochrome c release from the
mitochondria and caspase-3 activation. After a series of
purification, Senthil et al. [18] revealed that the withano-
lide 5Á-ethoxy-1-oxo-6b, 14a, 17b, 20-tetrahydroxy-20S,
22R-witha-2, 24-dienolide exhibited an activity compara-
ble to that of the crude extract. Third, the methanolic root
extracts, at doses of 65–265 ug/ml, down-regulated
expression of p34cdc2, a cell-cycle regulatory protein and
could lead to the growth arrest at the G2/M phase. Inter-
estingly, the extract utilized in this study also did not con-
tain withaferin A [19]. Fourth, with molecular simulation
withaferin A has been shown to target a threonine residue
of proteasomal chymotrypsin and inhibit its chymot-
rypsin-like activity in human prostate cancer cultures and
xenografts. It results in accumulation of ubiquitinated
proteins and the three proteasome target proteins (Bax,
p27, and IkappaB-alpha) accompanied by androgen
receptor protein suppression and apoptosis induction.
The ubiquitin proteasome pathway is now widely recog-
nized as an important target for drug discovery, because
many important intracellular processes, such as cell cycle
progression are orchestrated through the orderly degrada-Journal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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tion of key regulatory protein factors [19,20]. Fifth, for
prostate tumors, withaferin A was able to sensitize andro-
gen receptor (AR)-positive PC-3 prostate tumor cell line to
androgen ablation therapy via the prostate apoptosis
response-4 (Par-4) gene. This has been initially shown to
be independent of p53- and PTEN cascades. Interestingly,
while individually, withaferin A and anti-androgens
induced neither Par-4 nor apoptosis in the cells, the com-
bination of both synergistically induced Par-4 and apop-
tosis [21]. Sixth, LASH, but not withaferin A, sensitized
human cancer cells to anti-cancer drugs suggesting that
the LASH may be employed in combination with antican-
cer drugs to yield an effective combinatorial anti-cancer
formulation [22]. And lastly, the LASH as well as purified
withaferin A both inhibited NF-κB activation by prevent-
ing the activation of IkappaB kinase beta via a thioalkyla-
tion-sensitive redox mechanism. Other steroidal lactones,
such as withanolide A and 12-deoxywithastramonolide,
showed less inhibitory activity [23]. Ichikawa et al. corrob-
orated this finding by showing the structure-function
studies on withaferin A and its analogues [24]. The study
further emphasized the importance of unsaturated lac-
tone moiety in ring A in withaferin A. Both studies
revealed the role of withaferin A in suppressing NF-κB
activity through inhibition of IKK leading to the suppres-
sion of phosphorylation and degradation of IB. Inhibition
of the transcriptional factor NF-κB activation was for-
warded as one of the crucial mechanisms in induction of
apoptosis, overcoming resistance mechanisms and inhibi-
tion of immune response and inflammation mechanisms
of ASH.
Crude extract versus pure compounds of ASH: 
Results from cell-based assays with functional 
RNAs
Our genomic-based screening for the bioactive compo-
nent in extracts from the leaves of ASH (LASH) that could
selectively kill tumor cells (and not normal cells) con-
sisted of two parts (Fig. 1) [16,17]. In the initial phase,
tumor-derived and normal cell lines were first treated with
crude extract of ASH then their cytotoxicity profiles were
studied. As we found an interesting high-degree of selec-
tivity by LASH in exerting its cytotoxic potential in cancer
cells, a functional gene screening strategy was then imple-
mented by treating tumor cells with LASH after stable
transfections of siRNAs in an array format. We expect that
the tumor cells that express either the siRNA or ribozyme
targeting a gene essential for the cytotoxic effect of a spe-
cific agent should show greater resistance to the particular
drug. For the siRNA library, since the sequence and target
of the siRNA species is known, we enforced a stringent cri-
terion to avoid false-negatives by choosing the cells that
have, at least, two siRNAs aimed at different regions to be
LASH-resistant. We found that the p53 pathway was a
main target of LASH. More importantly, LASH was able to
activate tumor suppressor functions of mutant p53 possi-
bly by inducing allosteric conformation changes based on
the gain of wild-type specific epitopes [16].
The second step was a phenotype-guided purification
scheme with reverse phase HPLC. By combination of phe-
notypic effects in cultured normal and cancer cells and
gene targets obtained by gene-silencing screenings, we
identified the active compounds and the target pathways.
To this end we were able to identify (i) withaferin A and i-
Factor (withanone) killed cancer cells, (ii) i-Factor caused
selective killing of cancer cells and (iii) p53 pathway was
selectively altered in cancer cells by i-Factor. Molecular,
biochemical and visual analysis also supported that while
withaferin A possessed significant toxicities in tumor cells,
it also inhibited cell proliferation in normal human
embryonic lung (TIG1 and MRC-5) fibroblasts. On the
other hand, the activity of (i-Factor) withanone was
highly selective only to tumor cells, leaving the normal
cells unscathed.
As both withanone and LASH gave similar selective cell
killing potentials, LASH could be deemed practical for
application in cancer management as the crude extract, if
proven as efficacious as is easily obtainable compared to
the pure compound (Fig. 2A). However, one of the major
hurdles in the development of botanical drugs is the lack
of scientific acceptance. Some interesting works have
emerged in the past few years that identified molecular
signatures of a mixture extracted from a medicinal plant
extract as opposed to a single component agent [25]. Such
insights were made possible through the application of
robust gene expression profiling analyses, like the micro-
array technology or other functional genomic assays, e.g.
with siRNAs or ribozymes.
A combined siRNA and ribozyme library screening identi-
fied key gene targets for LASH crude extract and its two
major anti-tumor components, withanone and withaferin
A. We then used the bioinformatics tool "Ingenuity Path-
way Analysis (IPA, Mountain View, CA, USA)" to explore
how our identified gene targets interact functionally with
each other and to gain insights from the differences of the
networks that may correlate with the agents' bioactivities.
IPA is a commercial, web-based interface that uses a vari-
ety of computational algorithms to identify and establish
cellular networks that statistically fit the input gene list
and/or expression values from experiments. The analysis
uses a database of gene interactions culled from literature
and updated every quarter of the year.
Given the limited coverage of the siRNA library (enriched
for genes involved in apoptosis, cell proliferation and
stress response) and the stringency of the ribozyme library
screening, gene targets isolated from LASH, withanoneJournal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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and withaferin A were found to be present in the IPA data-
base. The predominant networks for the three agents are
shown in Fig. 2B. The top three nodes that act as highly
connected hubs are: BRCA1, MYC, and BLM for LASH;
BRCA1, MYC and c-JUN for withanone; BRCA1, JAK2 and
TERT for withaferin A. Additionally, the cellular networks
of the LASH showed greater similarity to withanone (i-
Factor) compared to that of withaferin A, and that these
interwoven pathways correlated with selectivity in tumor
action of the former two agents. It appears from our data
that a novel target by withanolides from W. somnifera is
the BRCA1, a transcription factor implicated in cell cycle
regulation, genome integrity, DNA damage response
(DDR). Only resveratrol (3,5,4'-trihydroxy-trans-stil-
bene), a dietary constituent found in grapes and wine, has
been found to exert anticancer activity by targeting BRCA1
in breast tumor cell lines [26].
Two studies on genomic comparisons of the crude extract
versus its pure bioactive compound have recently been
published. Yang et al. [27] performed a comparative phar-
macogenomic analysis between Anoectochilus formosanus
extract, a folk remedy from Taiwan, and its known anti-
cancer bioactive component, plumbagin. Using MCF-7
breast cancer cells, they noted that while the pure plum-
bagin up-regulated 50 known genes and down-regulated
Diagram of a cell-based genomic-screening for anti-proliferative components of LASH Figure 1
Diagram of a cell-based genomic-screening for anti-proliferative components of LASH. Tumor cells were stably 
transfected either with a siRNA array or a ribozyme library. After exposure to the crude extracts, gene targets were identified. 
Bioassay-guided purification was done to isolate the active component for the crude extracts. The p53 gene, a convenient tar-
get, was among the initial genes identified with LASH.Journal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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Molecular networks of crude extracts, withanone and withaferin A Figure 2
Molecular networks of crude extracts, withanone and withaferin A. (A) HPLC fractionation and characterization of 
the components with anti-tumor activities. LASH crude extract and withanone showed greater selectivity for tumor when 
assayed in parallel with normal cells. Details of the bioassays conducted are described in Widodo et al. [16]. (B) IPA-generated 
networks of the withanolides. Shaded node indicates that the gene was included in the input list of genes derived from siRNA/
ribozyme screening. A solid line without arrow indicates protein-protein interaction. Arrows indicate the direction of action 
(either with or without binding) of one gene to another. (C) Pathway comparisons. Fisher's exact test was used at p = 0.05 
level to determine whether a biological assignment could be explained by chance alone. Apparent from the canonical pathways, 
LASH statistically impacted on only three pathways, whereas the effects of withanone and withaferine A were more spread.Journal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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30 others, crude extract that in theory contains a more
complicated brew of phyto-compounds, surprisingly
affected only half the number of genes at >3-fold differ-
ence in expression levels. Subsequent confirmation with
Western analysis identified differential oncogenic signal-
ing pathways for the cell killing effects of the two agents:
the crude extract up-regulated caspase 8 and cytochrome c
and caused apoptosis predominantly while plumbagin
resulted in an induction of the cell-cycle checkpoint gene
p21 and DNA topoisomerase II leading to cell cycle arrest
[27]. The study has provided evidence that the individual
components and the crude extract may cause differential
signal transductions and the effect of the crude extract
may not be the cumulative effect of all of its components.
Accordingly, the biological response such as cytostasis or
apoptosis may vary depending on the individual compo-
nents and their composite mixture.
Differences in the gene profiles of the hypothalamus of
rats that were administered either by St. John's wort
(Hypericum perforatum) or imipramine, a synthetic anti-
depressant drug, were very intriguing. H. perforatum is one
of the most popular herbal medicines in Europe and
North America, and it is taken by people who suffer from
seasonal mood disorders and other types of depression.
Hypothalamus was chosen because of its known impor-
tance in mood altering functions, and it was suggested
that the St. John's wort and imipramine could be expected
to share some common pathways leading to their similar
beneficial effects. The arrays used by Wong et al. con-
tained 8799 rat genes plus ESTs [28]. To the authors, the
results were said to be disappointing since crude extracts
of H. perforatum differentially regulated a total of only 66
genes, in comparison to imipramine that affected 74
genes. Although variety of different pathways were repre-
sented by these genes, the surprising finding was that only
six genes were common to the treatments in spite of the
similar physiological effects on the animals. In addition to
these small numbers, the actual magnitude of the changes
was generally small (<2-fold change), although these were
claimed to be significant [28]. The study identified the
critical signal transduction pathways involved in the bio-
logical response and also suggested that the minor
changes in gene expression are sufficient to evoke major
responses.
It has often been assumed that the whole crude extract is
more useful than each of the purified component because
of synergistic actions. On the contrary, based on our find-
ing and observations from other investigators, it is inter-
esting to note that the purified components, i.e.
withanone and withaferin A, showed greater diversity in
affected pathways such as those relevant to apoptosis,
death receptor signaling, endoplasmic reticulum (ER)
stress and NF-KB signaling, as compared to the crude
LASH extract. The most significant canonical pathways
associated with the crude extract LASH were cell cycle
checkpoint/G2-M transition GM-CSF signaling and p53
signaling (Fig. 2C).
Thus, as it seems paradoxical that the sum of pathways for
individual components would, on the contrary, yield to a
lesser number compared with the crude extract, a global
analysis of the interactome of the five components
(wihtanone, withaferin A and three uncharacterized frac-
tions) may provide a rational explanation. As shown in
Fig. 3, a simplified representation of network-web showed
that the crude extract from LASH occupy the central 'hub'
position interconnecting all the pathways representing its
individual components. This apparent 'design principle'
implicates a special property of the crude extract since the
individual components branch-off with robust yet low-
connectivity networks, the crude extract maintained the
essential few network hub that have the greatest overall
effect on cell growth and proliferation. We hypothesize
that the interaction between components of the crude
extracts may either lead to a synergy of cell killing effects
or neutralize the toxicity of each other. This could be sig-
nificant to the greater appreciation of herbal preparation
in mainstream medicine.
Traditional medicines and inspirations from 
systems biology: Concluding remarks
Recent developments in computational biology and bio-
informatics have provided biologists with some system-
atic methods to analyze these molecular networks in a
cellular context. Collectively predicated as systems biol-
ogy, it aims to analyze relationships among elements
(nodes) in a given system or the emergent properties of
the system. Cellular networks that model the cellular
response to a given perturbation would include protein-
protein interaction networks (PPI: encode the informa-
tion of proteins and their physical interactions); signal
transduction and gene regulatory networks (STN and
GRN: show regulatory relationships between transcrip-
tion factors and/or regulatory RNAs, as well as the signal-
ing pathways that confer these responses); and the
metabolic networks (MN: illustrates the biochemical reac-
tions between metabolic substrates and products). Molec-
ular networks that occur in a cell can be presented as
either directed or undirected graphs. For example, PPI net-
works use undirected graphs where nodes represent pro-
teins and the links show the physical interactions between
the proteins. An exhaustive description of these networks
is available [29].
What insights can we gain by analyzing the web of com-
plexity of these networks associated with herbal drug
action in a cell in system biology perspective? We should
expect a major contribution from the bio-informaticsJournal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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Global topology of the network interactions among the components of the crude extract Figure 3
Global topology of the network interactions among the components of the crude extract. Each box network 
identified by IPA based on the input gene list corresponding to the gene target of each HPLC purified component. Note, the 
centrality of the molecular network affected by the crude extract. This could indicate a synergism of all the components could 
lead to a convergence to that of the crude extract.Journal of Translational Medicine 2008, 6:14 http://www.translational-medicine.com/content/6/1/14
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resources towards the development and enrichment of
traditional herbal medicine because such a perspective
captures the uniqueness and complexity of drug action in
a cell. Such holistic perspective also avoids the pitfall of
being too reductionist, and in effect, mollifies some criti-
cisms from traditional ethnopharmacologic researchers.
By going to a reverse direction, our current study likewise
tells us that by looking at the entire system of a crude for-
mulation, we can focus on some key central genes, in the
case of W. somnifera, withanolides is BRCA1, with which
the entire summation of network of the individual com-
ponent may have greater probability for convergence.
These targets are most likely vulnerable sites in a cancer
cell. Kawamura et al. demonstrated the practical implica-
tion of working on the 'genomic screening'-guided purifi-
cation in isolation of non-toxic, active component in
Japanese herbal medicine formulation Keishi-bukuryo-
gan (KGB) that regulates transcription of hemeoxygenase-
1 [30]. However, although these biological phenomena
are regarded with assumption of a real cellular mecha-
nism, we should be cautious at the same time that these
leads may not be definite and are dependent on the qual-
ity of the herbal preparation.
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